The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis

Nature Immunology

Volumn 16, Issue 6, 2015, Pages 618-627

  Onizawa, Michio ^a   Oshima, Shigeru ^a,d   Schulze Topphoff, Ulf ^a   Oses Prieto, Juan A ^b   Lu, Timothy ^a   Tavares, Rita ^a   Prodhomme, Thomas ^a   Duong, Bao ^a   Whang, Michael I ^a   Advincula, Rommel ^a   Agelidis, Alex ^a   Barrera, Julio ^a   Wu, Hao ^c   Burlingame, Alma ^b   Malynn, Barbara A ^a   Zamvil, Scott S ^a   Ma, Averil ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

A20 PROTEIN; DEUBIQUITINASE; PHOSPHOTRANSFERASE; RIPK1 KINASE; UNCLASSIFIED DRUG; CYSTEINE PROTEINASE; MULTIPROTEIN COMPLEX; PROTEIN BINDING; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK1 PROTEIN, MOUSE; RIPK3 PROTEIN, MOUSE; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, MOUSE; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL PROTECTION; CELL SURVIVAL; FIBROBLAST; IMMUNOPRECIPITATION; INFLAMMATORY DISEASE; MOUSE; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; UBIQUITINATION; ANIMAL; APOPTOSIS; C57BL MOUSE; ENZYME ACTIVE SITE; GENETICS; HUMAN; JURKAT CELL LINE; KNOCKOUT MOUSE; METABOLISM; NECROSIS; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CATALYTIC DOMAIN; CYSTEINE ENDOPEPTIDASES; FIBROBLASTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JURKAT CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; NECROSIS; PROTEIN BINDING; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; T-LYMPHOCYTES; UBIQUITINATION; UBIQUITINS;

EID: 84929899399     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3172     Document Type: Article

References (53)

1. Opipari, A. W. Jr. , Boguski, M. S. & Dixit, V. M. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J. Biol. Chem. 265, 14705-14708 (1990).
2. Lee, E. G. et al. Failure to regulate TNF-induced NF-B and cell death responses in A20-deficient mice. Science 289, 2350-2354 (2000).
3. Wertz, I. E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-B signalling. Nature 430, 694-699 (2004).
4. Boone, D. L. et al. The ubiquitin modifiying enzyme A20 is essential for terminating TLR signaling. Nat. Immunol. 5, 1052-1060 (2004).
5. Ma, A. & Malynn, B. A. A20: linking ubiquitination with immunity and human diseases. Nat. Rev. Immunol. 12, 774-785 (2012).
6. Catrysse, L. , Vereecke, L. , Beyaert, R & van Loo, G. A20 in inflammation and autoimmunity. Trends Immunol. 35, 22-31 (2014).
7. Musone, S. et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat. Genet. 40, 1062-1064 (2008).
8. Adrianto, I. et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat. Genet. 43, 253-258 (2011).
9. Turer, E. E. et al. Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J. Exp. Med. 205, 451-464 (2008).
10. Hitotsumatsu, O. et al. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 28, 381-390 (2008).
11. Kool, M. et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 35, 82-96 (2011).
12. Hammer, G. E. et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat. Immunol. 12, 1184-1193 (2011).
13. Matmati, M. et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat. Genet. 43, 908-912 (2011).
14. Heger, K. et al. A20 deficient mast cells exacerbate inflammatory responses in vivo. PLoS Biol. 12, e1001762 (2014).
15. Tavares, R. M. et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 33, 181-191 (2010).
16. Chu, Y. et al. B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 117, 2227-2236 (2011).
17. Hövelmeyer, N. et al. A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur. J. Immunol. 41, 595-601 (2011).
18. Chen, Z. J. & Sun, L. J Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cell 33, 275-286 (2009).
19. Lu, T. T. et al. Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 38, 896-905 (2013).
20. Lin, S. C. et al. Molecular basis for the unique deubiquitinating activity of the NF-B inhibitor A20. J. Mol. Biol. 376, 526-540 (2008).
21. Shembade, N. , Ma, A. & Harhaj, E. W. Inhibition of NF-B signaling by A20 through disruption of ubiquitin enzyme complexes. Science 327, 1135-1139 (2010).
22. Bosanac, I. et al. Ubiquitin binding to A20 ZnF4 is required for modulation of NF-B signaling. Mol. Cell 40, 548-557 (2010).
23. Skaug, B. et al. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol. Cell 44, 559-571 (2011).
24. Tokunaga, F. et al. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-B regulation. EMBO J. 31, 3856-3870 (2012).
25. Verhelst, K. et al. A20 inhibits LUBAC-mediated NF-kB activation by linear polyubiquitin chains via its zinc finger 7. EMBO J. 31, 3845-3855 (2012).
26. Beyaert, R. , Heyninck, K. & Van Huffel, S. A20 and A20 binding proteins as cellular inhibitors of NF-B dependent gene expression and apoptosis. Biochem. Pharmacol. 60, 1143-1151 (2000).
27. Chen, I. L. , Tsau, J. S. , Molkentin, J. D. , Komatsu, M. & Hedrick, S. M. Mechanisms of necroptosis in T cells. J. Exp. Med. 208, 633-641 (2011).
28. Osborn, S. L. et al. Fas-associated death domain (FADD) is a negative regulator of T-cell receptor mediated necroptosis. Proc. Natl. Acad. Sci. USA 107, 13034-13039 (2010).
29. He, S. et al. Receptor interacting protein kinase 3 determines cellular necroptotic responses to TNFa. Cell 137, 1100-1111 (2009).
30. Cho, Y. et al. Phosphorylation-driven assembly of the RIPK1-RIPK3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137, 1112-1123 (2009).
31. Li, J. et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 150, 339-350 (2012).
32. Zamvil, S. S. & Steinman, L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8, 579-621 (1990).
33. Cua, D. J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748 (2003).
34. Linkermann, A. & Green, D. R. Necroptosis. N. Engl. J. Med. 370, 455-465 (2014).
35. Udeshi, N. D. , Mertins, P. , Svinkina, T. & Carr, S. A. Large-scale identification of ubiquitination sites by mass spectrometry. Nat. Protoc. 8, 1950-1960 (2013).
36. Vanlangenakker, N. et al. TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members. Cell Death Dis. 2, e230 (2011).
37. Duong, B. et al. A20 restricts ubiquitination of pro-interleukin-1 protein complexes and suppresses NLRP3 inflammasome activity. Immunity 42, 55-67 (2015).
38. Opipari, A. W. , Hu, H. M. , Yabkowitz, R. & Dixit, V. M. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J. Biol. Chem. 267, 12424-12427 (1992).
39. Welz, P. S. et al. FADD prevents RIPK3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 477, 330-334 (2011).
40. Bates, J. S. et al. Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations. Genes Immun. 10, 470-477 (2009).
41. Jiang, X. et al. Expression of tumor necrosis factor induced protein 3 mRNA in peripheral blood mononuclear cells negatively correlates with disease severity in psoriasis vulgaris. Clin. Vaccine Immunol. 19, 1938-1942 (2012).
42. Kelly, C. et al. Expression of the inflammatory regulator A20 correlates with lung function in patients with cystic fibrosis. J. Cyst. Fibros. 12, 411-415 (2013).
43. Kaiser, W. J. et al. RIPK3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471, 368-372 (2011).
44. Oberst, A. et al. Catalytic activity of the caspase-8-FLIPL complex inhibits RIPK3-dependent necrosis. Nature 471, 363-367 (2011).
45. Zhang, H. et al. Functional complementation between FADD and RIPK1 in embryos and lymphocytes. Nature 471, 373-376 (2011).
46. O'Donnell, M. A. et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat. Cell Biol. 13, 1437-1442 (2011).
47. Moquin, D. M. et al. CYLD deubiquitinates RIP1 in the TNF-induced necrosome to facilitate kinase activation and programmed necrosis. PLoS ONE 8, e76841 (2013).
48. Bertrand, M. J. et al. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 30, 789-801 (2009).
49. Bertrand, M. J. et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIPK1 ubiquitination. Mol. Cell 30, 689-700 (2008).
50. McComb, S. et al. cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation. Cell Death Differ. 19, 1791-1801 (2012).
51. Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIPK3 kinase. Cell 148, 213-227 (2012).
52. Xie, T. et al. Structural insights into RIPK3-mediated necroptotic signaling. Cell Rep. 5, 70-78 (2013).
53. Molnarfi, N. et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J. Exp. Med. 210, 2921-2937 (2013).